|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Roche (RHHBY)'s Lucentis Works to Treat Vision Loss from Diabetes
7/24/2012 8:22:53 AM
Roche Holding AG (ROG)’s Lucentis works to treat a leading cause of blindness associated with diabetes, U.S. regulators said. The injection improved vision in people with diabetic macular edema, Food and Drug Administration staff said in a report today ahead of a July 26 meeting of agency advisers on expanding approval of Lucentis. The drug is already used to treat wet age-related macular degeneration. Both diseases involve swelling of the macula, in the center of the retina. Lucentis, if approved, would be the first drug cleared for diabetic macular edema. More than 500,000 people in the U.S. have the disease, Anthony Adamis, vice president and global head of ophthalmology at Roche’s Genentech unit said in a telephone interview. Patients now receive laser therapy. Regeneron Pharmaceuticals Inc. (REGN), based in Tarrytown, New York, is studying its Eylea to treat the condition.
|
|
|
|
|
|
|
|
|
|
|